Considering the Use of Female Hormone Therapy in Women With Cerebral Cavernous Malformations: An Editorial. (18th April 2023)

• Record Type: Journal Article
• Authors: Madsen, Tracy E.; Rexrode, Kathryn
• Is Part Of: Neurology. Volume 100:Number 16(2023)
• Page Start: 744
• Page End: 745
• Publication Date: 2023-04-18
• Subjects: Neurology -- Periodicals; Neurology -- Periodicals; Neurologie -- Périodiques; 616.8
• DOI: 10.1212/WNL.0000000000207128
• Languages: English
• ISSNs: 0028-3878

Abstract

Abstract : Understanding the role of exogenous hormone therapy (e.g., oral contraception [OCP] or menopausal hormone therapy [MHT]) in stroke risk is critical for risk factor assessment and modification in female patients of all ages. For OCPs, in population-based studies and meta-analyses, data on risk of intracranial hemorrhage (ICH) associated with OCPs suggest little to no increased risk, 1, 2 although there may be a small increased risk of subarachnoid hemorrhage. 1 For MHT, randomized trial data do not suggest an increased risk of hemorrhagic stroke. 3 Little is known, however, about hemorrhagic stroke risk associated with exogenous hormones in female patients with cerebral cavernous malformation (CCM) specifically.